Business Description
Alumis Inc
NAICS : 541714
SIC : 2834
ISIN : US0223071020
Description
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 11.64 | |||||
| Equity-to-Asset | 0.84 | |||||
| Debt-to-Equity | 0.09 | |||||
| Debt-to-EBITDA | -0.13 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | N/A/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 38.83 | |||||
| 9-Day RSI | 38.67 | |||||
| 14-Day RSI | 39.12 | |||||
| 3-1 Month Momentum % | 4.7 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 11.26 | |||||
| Quick Ratio | 11.26 | |||||
| Cash Ratio | 10.8 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | -6.28 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -101.1 | |||||
| ROIC % | -569.27 | |||||
| ROC (Joel Greenblatt) % | -696.1 | |||||
| ROCE % | -116.34 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.37 | |||||
| Price-to-Tangible-Book | 1.31 | |||||
| EV-to-EBIT | -0.66 | |||||
| EV-to-Forward-EBIT | -0.6 | |||||
| EV-to-EBITDA | -0.66 | |||||
| EV-to-FCF | -0.73 | |||||
| Price-to-Net-Current-Asset-Value | 1.46 | |||||
| Price-to-Net-Cash | 1.53 | |||||
| Earnings Yield (Greenblatt) % | -151.52 | |||||
| FCF Yield % | -45.24 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ALMS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Alumis Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -26.808 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 39.12 | ||
| 14-Day ATR ($) | 0.86101 | ||
| 20-Day SMA ($) | 9.2595 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 7.66 - 13.53 | ||
| Shares Outstanding (Mil) | 54.41 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Alumis Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Alumis Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Alumis Inc Frequently Asked Questions
What is Alumis Inc(ALMS)'s stock price today?
The current price of ALMS is $8.39. The 52 week high of ALMS is $13.53 and 52 week low is $7.66.
When is next earnings date of Alumis Inc(ALMS)?
The next earnings date of Alumis Inc(ALMS) is 2025-02-28 Est..
Does Alumis Inc(ALMS) pay dividends? If so, how much?
Alumis Inc(ALMS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers